On March 9, 2021 PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, reported that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec) (Press release, PerkinElmer, MAR 9, 2021, View Source [SID1234576322]). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Oxford Immunotec’s global role in fighting tuberculosis, particularly its trademark product, the T-SPOT.TB test, and the operations it has built are remarkable," said Prahlad Singh, PerkinElmer president and chief executive officer. "We recognize the distinct clinical and logistical advantages of the test and see a great opportunity to leverage our automation capabilities and commercial channel access to bring tuberculosis testing to more customers around the world."

Headquartered in Abingdon, UK, Oxford Immunotec is recognized as a global leader of proprietary test kits for latent tuberculosis. Its Interferon Gamma Release Assay (IGRA) offering identifies individuals who are infected with tuberculosis. Oxford Immunotec had approximately 275 global employees as of September 30, 2020 and reported total revenue from continuing operations of $73.74 million and $39.2 million as of the fiscal year ended December 31, 2019 and the nine months ended September 30, 2020, respectively.

On March 9, 2021 NeuBase Therapeutics, Inc. (NASDAQ: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, reported that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference (Press release, NeuBase Therapeutics, MAR 9, 2021, View Source [SID1234576321]). Both virtual investor conferences take place in March 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:
Event: H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9th
Time: 7:00 a.m. ET
Location: Webcast Link – or at the company’s website (click here)


Event: Oppenheimer 31st Annual Healthcare Conference
Date: Wednesday, March 17th
Time: 11:20 a.m. ET
Location: Webcast Link – or at the company’s website (click here)
The webcasts from both conferences will also be archived on the NeuBase website, www.neubasetherapeutics.com.

On March 9, 2021 ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), reported the completion of their previously announced 100% stock-for-stock merger (Press release, NantKwest, MAR 9, 2021, https://nantkwest.com/immunitybio-and-nantkwest-complete-merger/ [SID1234576320]). This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of NantKwest at its Special Meeting held on March 8, 2021. The combined company will operate under the name ImmunityBio, Inc. ("ImmunityBio") and its shares of common stock will commence trading on NASDAQ on March 10, 2021 under the new ticker "IBRX."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ImmunityBio is the culmination of a decades-long quest to orchestrate natural killer cells and T cells to induce what we call ‘immunogenic cell death’. By integrating novel immunotherapy molecules with a state-of-the-art natural killer cell therapy and viral vectors, we are now in the position to transform treatments for patients afflicted with cancer and infectious diseases by activating the host immune system," said Patrick Soon-Shiong, M.D., Executive Chairman of the ImmunityBio Board. "With the merger complete, ImmunityBio has the scale that will allow us to advance our development of more novel therapies in oncology and infectious diseases, and accelerate work on our unique COVID-19 vaccine, which we believe is key to creating long-term immunity to the SARS-CoV-2 virus."

"We are excited to bring together these innovative organizations and talented teams to create a leading immunotherapy and cell therapy company," said Rich Adcock, Chief Executive Officer of ImmunityBio. "Together we expect to deliver important new treatments for patients, as we leverage our best-in-class platforms, expertise and resources to further accelerate our pipeline. We believe that our teams are prepared to seamlessly execute our go-forward strategy. We are excited to deliver on our mission on behalf of our shareholders, partners, and other stakeholders."

Transaction Details

Pursuant to the merger, the former stockholders of ImmunityBio are entitled to receive 0.8190 of a share of NantKwest common stock for each outstanding share of ImmunityBio common stock that they held immediately prior to the merger. Former ImmunityBio stockholders should contact American Stock Transfer & Trust Company, LLC, the exchange agent for the transaction, by calling toll-free at (877) 248-6417 or at (718) 921-8317, if they have any questions regarding the consideration to which they are entitled.

On March 9, 2021 NanOlogy, LLC, a clinical-stage oncology company, reported that enrollment has been completed in its clinical trial of NanoDoce for bladder cancer (Press release, NanOlogy, MAR 9, 2021, View Source [SID1234576319]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Local bladder cancer at high risk for progression often requires removal of the bladder resulting in a severe lifelong quality of life issues. NanOlogy enrolled 36 bladder cancer patients in a Phase 1/2 two-arm trial evaluating direct injection/instillation of NanoDoce Suspension.

The first arm (n=19) included patients with high risk nonmuscle invasive bladder cancer. A high majority to date had a complete response at 3 months with 12 month data available in 2Q2021.

The second arm (n=17) included patients with muscle invasive bladder cancer. More than half have retained their bladder with no intervention at the initial study endpoint, now extended up to 12 months to test durability. These preliminary results will be updated and published once final.

On March 9, 2021 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, reported that it will publish its results for the financial year 2020 on March 15, 2021 at 10:00 pm CET (5:00 pm EDT) (Press release, MorphoSys, MAR 9, 2021, View Source [SID1234576318]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MorphoSys’ Management team will host a conference call and webcast on March 16, 2021 at 2:00 pm CET (9:00 am EDT) to present results for the financial year 2020 and provide an outlook for 2021.

The conference call will start with a presentation by the Management team followed by a Q&A session. Presenters will be:

– Jean-Paul Kress, M.D., Chief Executive Officer

– Sung Lee, Chief Financial Officer

– Roland Wandeler, Ph.D., Chief Operating Officer

– Malte Peters, M.D., Chief Research & Development Officer